The first study, by Moreau et al., explores the feasibility of using 68Ga-prostate-specific membrane antigen (PSMA) 11 PET/CT in comparison with 18F-FDOPA PET/CT to detect early recurrence in glioblastoma patients. Here, FOLH1 is linked to glioblastoma.